These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 15560944)
1. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Friede M; Aguado MT Adv Drug Deliv Rev; 2005 Jan; 57(3):325-31. PubMed ID: 15560944 [No Abstract] [Full Text] [Related]
3. Trends in particulate antigen and DNA delivery systems for vaccines. Gander B Adv Drug Deliv Rev; 2005 Jan; 57(3):321-3. PubMed ID: 15560943 [No Abstract] [Full Text] [Related]
4. Mucosal delivery of vaccine antigens and its advantages in pediatrics. De Magistris MT Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335 [TBL] [Abstract][Full Text] [Related]
5. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Alpar HO; Somavarapu S; Atuah KN; Bramwell VW Adv Drug Deliv Rev; 2005 Jan; 57(3):411-30. PubMed ID: 15560949 [TBL] [Abstract][Full Text] [Related]
6. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
7. Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z; Leong KW J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136 [TBL] [Abstract][Full Text] [Related]
8. Delivery systems for molecular vaccination. Sheikh NA; al-Shamisi M; Morrow WJ Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651 [TBL] [Abstract][Full Text] [Related]
9. Microparticles as vaccine adjuvants and delivery systems. O'Hagan DT; Singh M Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577 [TBL] [Abstract][Full Text] [Related]
10. Bioadhesive delivery systems for mucosal vaccine delivery. Baudner BC; O'Hagan DT J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314 [TBL] [Abstract][Full Text] [Related]
11. [Adjuvants--essential components of new generation vaccines]. Dzierzbicka K; Kołodziejczyk AM Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510 [TBL] [Abstract][Full Text] [Related]
12. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
13. Synthetic vehicles for DNA vaccination. van den Berg JH; Nuijen B; Schumacher TN; Haanen JB; Storm G; Beijnen JH; Hennink WE J Drug Target; 2010 Jan; 18(1):1-14. PubMed ID: 19814658 [TBL] [Abstract][Full Text] [Related]
14. A need for effective adjuvants. Bunce CJ; Morse MA Curr Opin Mol Ther; 2003 Feb; 5(1):8-9. PubMed ID: 12669464 [No Abstract] [Full Text] [Related]
19. Particulate delivery systems for vaccines: what can we expect? Bramwell VW; Perrie Y J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973 [TBL] [Abstract][Full Text] [Related]
20. Novel approaches to pediatric vaccine delivery. O'Hagan DT; Rappuoli R Adv Drug Deliv Rev; 2006 Apr; 58(1):29-51. PubMed ID: 16480788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]